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Abstract
Background: In transfusion-dependent anaemias, while absolute serum ferritin levels broadly correlate with
liver iron concentration (LIC), relationships between trends in these variables are unclear. These
relationships are important because serum ferritin changes are often used to adjust or switch chelation
regimens when liver magnetic resonance imaging (MRI) is unavailable. Objectives and methods: This post
hoc analysis of the EPIC study compared serum ferritin and LIC in 317 patients with transfusion-
dependent thalassaemia before and after 1 yr of deferasirox. Results: Serum ferritin responses
(decreases) occurred in 73% of patients, 80% of whom also have decreased LIC. However, 52% of
patients without a serum ferritin response did decrease LIC and by >1 mg Fe/g dw (median 3.9) in 77% of
cases. Absolute serum ferritin and LIC values correlated significantly only when serum ferritin was
<4000 ng/mL (r = 0.59; P < 0.0001) and not at higher levels (≥4000 ng/mL; r = 0.19). Serum ferritin
response was accompanied by decreased LIC in 89% and 70% of cases when serum ferritin was <4000
or ≥4000 ng/mL, respectively. Conclusions: As serum ferritin nonresponse was associated with LIC
decrease in over half of patients, use of liver MRI may be particularly useful for differentiating true from
apparent non-responders to deferasirox based on serum ferritin trends alone.
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Iron chelation therapy is critical for reducing and preventing
iron-induced endocrine, cardiac and hepatic complications in
patients with various chronic transfusion-dependent anaemias
(1–5). As serum ferritin is elevated in iron overload (6) and
is a simple, repeatable and inexpensive method, its measure-
ment plays a key role in assessing iron overload and
response to chelation therapy (6–8).
Long-term control of serum ferritin over several years is a
key goal of iron chelation therapy. Ideally, patients will
achieve and maintain a serum ferritin value of below
1000 ng/mL, which is associated with higher survival rates
and improved cardiac and liver function than higher serum
ferritin levels (3, 9). Appropriate chelation therapy has been
shown to reduce liver and myocardial iron overload. Serum
ferritin correlates signiﬁcantly with liver iron concentration
(LIC) (10–13), but correlates weakly with myocardial T2*
(mT2*) (14–16). Clinical practice guidelines for transfusion-
dependent thalassaemias recommend serial measurement of
serum ferritin at regular intervals to monitor iron chelation
efﬁcacy (17, 18). However, monitoring patients by serum
ferritin levels requires not only interpretation of absolute val-
ues, but also interpretation of trends (sequential changes), so
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chelation regimens can be adjusted or modiﬁed when neces-
sary. Successful application of serum ferritin for monitoring
chelation therapy requires a good understanding of the asso-
ciation between serum ferritin and LIC responses across a
wide spectrum of iron burdens, as well as for different
chelation regimens. Several studies have reported signiﬁcant
cross-sectional correlations of absolute serum ferritin values
with LIC values, measured by a variety of methods (10–13),
although the R2 values were often low, which is indicative
of the small effect size of serum ferritin. However, relatively
little has been reported regarding the predictive utility of
serum ferritin trends over time. This may have practical
implications because the absence of a serum ferritin response
in the ﬁrst few months of a new chelation regimen could be
interpreted as a lack of response with respect to decrease in
body iron load, even when patients may be experiencing a
reduction in LIC (19).
Serum ferritin levels can be elevated independently of iron
levels by factors such as acute or chronic inﬂammation and by
acute or chronic liver damage (9, 20, 21). Serum ferritin levels
may also be affected by frequency of blood transfusion (20),
iron distribution between hepatocytes and macrophages (22,
23), type of iron chelation therapy used (24) and the duration
of chelation therapy (25). Finally, at values between 3000 and
4000 ng/mL, iron-free serum ferritin is secreted by macro-
phages at levels that are approximately proportional to body
iron stores. However, when serum ferritin values are higher
than this, an increasing proportion of serum ferritin becomes
iron-rich tissue ferritin that has leaked from damaged hepato-
cytes (26). Thus, the relationship between serum ferritin and
LIC, and trends in response to iron chelation therapy, may also
differ at high serum ferritin levels, although this has yet to be
systematically addressed.
Liver iron concentration determination is less affected by
factors unrelated to iron overload than serum ferritin and is a
reliable and predictable measure of absolute body iron stores
up to levels of approximately 30 mg Fe/g dw (27), as well as
changes over time. Body iron stores can be calculated from
the LIC: total body iron (mg Fe/kg) = 10.6 9 LIC (mg Fe/g
dw) (28). Hence, LIC changes over time are frequently used
to measure net iron balance during chelation therapy. Mag-
netic resonance imaging (MRI), when available, is a widely
accepted non-invasive method for assessing LIC (29, 30) and
offers advantages such as sensitivity to low levels of iron
load and high reproducibility (29, 31), although R2 MRI
(FerriScan) becomes less reliable when LIC is above
30 mg Fe/g dw (27). Nevertheless, in some areas of the
world, specialist requirements and cost may limit the wide-
spread use of MRI for monitoring iron chelation efﬁcacy. In
the absence of access to MRI, the judicious use and interpre-
tation of serum ferritin levels and trajectories become critical
to effective patient management.
Therefore, it is important to understand the utility and limi-
tations of serial serum ferritin measurements in prediction of
responses to chelation regimens. The Evaluation of Patients’
Iron Chelation with Exjade (EPIC) study (32) provides a par-
ticularly valuable cohort of patients to address these questions
as serum ferritin and liver MRI data are available in a large,
prospective cohort of patients on a single chelation therapy
modality. Therefore, this post hoc analysis of the EPIC study
was conducted to gain insight into the relative trajectories of
LIC and serum ferritin, across a range of iron burdens, before
and after 1 yr of deferasirox treatment in patients with thalas-
saemia and transfusional iron overload. Speciﬁcally, we
wanted to aid clearer interpretation of the relationship between
changes in serum ferritin and LIC, and to identify factors that
predict true versus pseudo non-response to chelation therapy
with deferasirox. Ultimately, we aimed to demonstrate how
serum ferritin trends can best be used to predict clinical
response during treatment with deferasirox and to provide evi-
dence-based practical guidance for patients with transfusion-
dependent thalassaemias.
Methods
Study design and patient population
EPIC was a prospective, multicentre, open-label, 1-yr trial of
the efﬁcacy and safety of deferasirox in 1744 patients with
transfusion-dependent anaemias (1115 patients with transfusion-
dependent thalassaemia), which was conducted between April
2005 and June 2008 across 23 countries (32). In a predeﬁned
liver MRI substudy, patients were recruited from 25 sites that
had the appropriate apparatus and expertise to perform liver R2-
MRI assessments (33). Patients included in this post hoc analy-
sis of EPIC had transfusion-dependent thalassaemia and had
both a R2-MRI-assessed LIC measurement and a serum ferritin
measurement at study baseline and after 1 yr. The design and
patient population of the EPIC study have been described previ-
ously (32). In brief, eligible patients were aged ≥2 yr and had
transfusional iron overload; deferasirox was started at a dose of
10–30 mg/kg/d. Initial dosing was individualised according to
the frequency of blood transfusions, but was adjusted thereafter
in line with serum ferritin trends and safety parameters. Written,
informed consent was obtained from all patients prior to study
participation. The EPIC study conformed to Good Clinical Prac-
tice guidelines and the Declaration of Helsinki.
Assessments
This analysis of the EPIC liver MRI substudy evaluated the
relationship between serum ferritin and LIC. Serum ferritin
levels were assessed at study baseline and every 4 wk there-
after. R2-MRI assessment of LIC was conducted at study
baseline and end of study (i.e. after 1 yr of deferasirox) with
standard 1.5-Tesla MRI scanners. MRI data were analysed
centrally by Inner Vision Biometrics Pty Ltd (Claremont,
WA, Australia) as previously reported (34).
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Statistical analyses
A receiver operating characteristic (ROC) analysis was con-
ducted to establish the serum ferritin levels that predict an
LIC threshold of 20 mg Fe/g dw; analyses were performed
for all patients with both LIC and serum ferritin measure-
ments, at baseline (n = 313) and at end of study (n = 311).
Summary statistics are provided for serum ferritin and LIC
responders (decrease) and non-responders (increase or no
change), and for study baseline serum ferritin categories
(≥4000 vs. <4000 ng/mL); analyses were based upon
patients with both LIC and serum ferritin measurements
available at end of study (n = 311). Pearson’s correlation
coefﬁcient (r) was used to measure correlations between
serum ferritin levels and LIC at study baseline, and change
from study baseline to end of study, and presented as scatter
plots. Patients were grouped according to study baseline iron
burden: LIC <15 or ≥15 mg Fe/g dw and serum ferritin
<2000, 2000 to <4000 or ≥4000 ng/mL. These categories
were chosen as clinically relevant thresholds and to allow
good balance across groups. An additional theoretical con-
sideration was that a greater proportion of serum ferritin
derives from damaged hepatocytes at serum ferritin levels
>4000 ng/mL (26).
Results
Patient characteristics
Of the 1744 patients comprising the EPIC study population,
317 patients with transfusion-dependent thalassaemia were
included in this analysis (Table 1). Of these, 313 and 311
patients had both LIC and serum ferritin measurements
available at baseline and end of study, respectively.
The mean age of patients included in this analysis was
20.4 yr. At study baseline, mean  SD duration of transfu-
sion therapy was 18.3  9.4 yr and most patients (n = 307/
317) had received prior chelation therapy. Median (range)
serum ferritin level [3675 (462–18 126) ng/mL] and
mean  SD LIC [22.1  12.6 mg Fe/g dw (range 2–55)]
were indicative of high body iron burden. Indeed, 140
patients had serum ferritin levels of 4000 ng/mL or more
and 196 patients had LIC levels of 15 mg Fe/g dw or more
at study baseline (Table 2). Approximately one-quarter of
patients had a prior history of hepatitis B and/or C.
Utility of serum ferritin measurements to predict LIC
A ROC analysis was performed to determine a serum fer-
ritin value that predicts an LIC of 20 mg Fe/g dw. The
results of that analysis indicated serum ferritin values of
3500 ng/mL at study baseline and 4000 ng/mL at end of
study predict this severely high liver iron burden in 83.2%
and 72.7% of patients, respectively (Table S1).
Trajectory of serum ferritin and LIC during chelation
therapy
Of the 311 patients analysed after 1 yr, 72.7% (n = 226)
were identiﬁed as achieving a serum ferritin response (i.e.
any decrease in serum ferritin levels after 1 yr) and 27.3%
(n = 85) were classiﬁed as non-responders (i.e. an increase
or no change in serum ferritin levels after 1 yr). LIC
decreased in approximately half of serum ferritin non-
responders (51.8%; n = 44/85) and in 79.6% of serum
ferritin responders (n = 180/226; Fig. 1A). Of the serum
ferritin non-responders with an LIC decrease, there was a
clinically relevant decrease in LIC of ≥1 mg Fe/g dw in
77% (n = 34/44) of patients [median (range) 3.9 (18.4
to 1.1) mg Fe/g dw; Fig. 1B]. In general, serum ferritin
responders had a lower median transfusional iron intake,
although the interquartile ranges overlap [median (in-
terquartile range) 0.3 (0.2–0.4) vs. 0.4 (0.3–0.4) mg/kg/
d), and received a higher deferasirox dose [median
(interquartile range) 28.1 (22.1–33.6) vs. 23.7 (20.2–
29.6) mg/kg/d] compared with serum ferritin non-
responders.
Table 1 Demographic and study baseline characteristics of the
patients from the EPIC study included in this subanalysis
Characteristics All patients (n = 317)
Mean age (range), yr 20.4 (2–53)
Male : female, n 148 : 169
Race (Caucasian : Oriental : other), n 144 : 157 : 16
History of hepatitis B and/or C, n (%) 91 (28.7)
Splenectomy, n (%) 147 (46.4)
Previous chelation therapy, n (%)
DFO monotherapy 215 (67.6)
DFP monotherapy 3 (0.9)
DFO and/or DFP1 89 (28.0)
Other2 1 (0.3)
None 10 (3.1)
Mean number of transfusion
sessions in the year prior
to study entry  SD (n = 316)
15.4  7.8
Mean total volume of RBCs
transfused in the year prior
to study entry  SD, mL/kg
(n = 312)
170.1  183.9
Mean  SD duration of
transfusion therapy, yr (n = 315)
18.3  9.4
Median serum ferritin (range),
ng/mL (n = 313)
3675 (462–18 126)
Mean LIC  SD (range), mg
Fe/g dw (n = 313)
22.1  12.6 (2–55)
DFO, deferoxamine; DFP, deferiprone; LIC, liver iron concentration;
RBC, red blood cell; SD, standard deviation.
1Patients received DFP and DFO but not necessarily in combination.
2Other category is not mutually exclusive; patients who received
either DFO and/or DFP and other chelation therapies are counted
under both categories.
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Analysis of serum ferritin and LIC response by study
baseline serum ferritin level: A serum ferritin response was
observed in more patients when study baseline serum ferritin
was ≥4000 ng/mL [79.9% (n = 111/139) vs. 66.9%
(n = 115/172) <4000 ng/mL; Fig. 2A]. However, more
serum ferritin responders had an LIC response with study
baseline serum ferritin <4000 ng/mL [88.7% (n = 102/115)]
compared with serum ferritin responders with study baseline
serum ferritin ≥4000 ng/mL [70.3% (n = 78/111); Fig. 2B].
The proportion of patients who decreased LIC despite hav-
ing no serum ferritin response was similar regardless of
serum ferritin study baseline category [52.6% (n = 30/57),
<4000 ng/mL; 50.0% (n = 14/28), ≥4000 ng/mL; Fig. 2B].
There was little change in median (range) LIC in serum fer-
ritin non-responders after 1 yr regardless of study baseline
serum ferritin value [0.3 (13.5 to 18.7) for <4000 ng/mL
and 0.2 (18.4 to 19.6) for ≥4000 ng/mL].
Assessment by change in serum ferritin and LIC quadrants
indicated that patients without a serum ferritin or LIC
response (n = 41) had the lowest study baseline median
(range) serum ferritin [2155 (480–9725) ng/mL) and LIC
(11.9 (1.8–37.5) mg Fe/g dw] and received a lower median
deferasirox dose [23.7 (9.7–36.0) mg/kg/d; Table S1]. Over-
all, median LIC decrease (mg Fe/g dw) was smaller in
patients with study baseline serum ferritin <4000 ng/mL
(n = 172) than in those with serum ferritin ≥4000 ng/mL
[2.8 (38.5 to 18.7) vs. 4.9 (31.1 to 19.6); n = 139).
Median iron intake was similar between groups (Table S2).
Relationship between serum ferritin levels and LIC by
study baseline iron burden
In total, 313 of 317 patients had both serum ferritin and LIC
determined at study baseline; 311 patients had both
measurements at end of study. In these patients, results of
the correlation analyses between serum ferritin levels and
LIC before and after 1 yr of deferasirox treatment (i.e. study
baseline and end of study) are summarised by iron burden in
Table 2. A higher positive correlation was observed between
serum ferritin and LIC at study baseline, and for change
from study baseline, when study baseline serum ferritin was
<4000 ng/mL (r = 0.59 and r = 0.51, respectively) than
when study baseline serum ferritin was ≥4000 ng/mL
(r = 0.19 and r = 0.37, respectively; Figure S1A,B). Simi-
larly, a higher positive correlation was observed between
serum ferritin and LIC at study baseline, and for change
from study baseline, when study baseline LIC was
<15 ng/mL (r = 0.53 and r = 0.62, respectively) than when
study baseline LIC was ≥15 ng/mL (r = 0.36 and r = 0.29,
respectively; Figure S1C,D).
The relationship between serum ferritin and LIC was eval-
uated further across a range of study baseline iron burden
categories. At study baseline, there was a moderate
(r = 0.37–0.48) and statistically signiﬁcant positive relation-
ship between LIC and serum ferritin levels in patients with
LIC <15 mg Fe/g dw and serum ferritin <4000 ng/mL
(P ≤ 0.005). However, a weak correlation was observed in
patients with serum ferritin ≥4000 ng/mL, regardless of
LIC (r = 0.14 and r = 0.09; P > 0.3; Table 2).
The mean changes from study baseline for serum ferritin
and LIC generally correlated more strongly than at study
baseline across iron burden categories (Table 2). Correlation
between change from study baseline in LIC and serum fer-
ritin was strongest in patients with LIC <15 mg Fe/g dw
and serum ferritin <4000 ng/mL, although a moderate
positive relationship was evident even at the highest level
of iron burden (LIC ≥15 mg Fe/g dw and serum ferritin
≥4000ng/mL, r = 0.36, P < 0.0001; Table 2).
Table 2 Correlation coefficients (r) between serum ferritin levels and LIC at study baseline and between serum ferritin and LIC mean change
from study baseline
Study baseline iron burden
Correlation coefficient between serum ferritin levels and LIC
Study baseline
Mean change from
study baseline
LIC (mg Fe/g dw) Serum ferritin (ng/mL) n r P-value r P-value
All <4000 172 0.591 <0.0001 0.51 <0.0001
All ≥4000 139 0.191 0.0248 0.37 <0.0001
<15 All 115 0.53 <0.0001 0.62 <0.0001
≥15 All 196 0.36 <0.0001 0.29 <0.0001
<15 <2000 55 0.37 0.005 0.56 <0.0001
2000 to <4000 49 0.48 0.0005 0.67 <0.0001
≥4000 11 0.14 0.69 0.62 0.04
≥15 <2000 12 0.55 0.07 0.32 0.32
2000 to <4000 56 0.06 0.64 0.41 0.002
≥4000 128 0.09 0.33 0.36 <0.0001
dw, dry weight; LIC, liver iron concentration.
1Based upon patients with both LIC and serum ferritin measurements available at study baseline (n = 173, serum ferritin <4000 ng/mL and
n = 140, serum ferritin ≤4000 ng/mL).
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Discussion
Serum ferritin measurements are frequently used to monitor
patients with transfusional iron overload, particularly in the
absence of access to MRI for LIC assessment. Despite the
widespread acceptance of serum ferritin as a surrogate mar-
ker of iron burden, few studies have investigated the rela-
tionships between changes in LIC and changes in serum
ferritin during iron chelation therapy. Indeed, this large-
scale, post hoc analysis of data from patients with transfu-
sion-dependent thalassaemia in the 1-yr, prospective EPIC
study is the ﬁrst to address these relationships in patients
treated with a single chelation modality.
In this analysis, a serum ferritin response predicted an LIC
response in 80% of patients with transfusion-dependent tha-
lassaemia treated with deferasirox for 1 yr. Thus, only 20%
of patients with a serum ferritin response did not respond in
terms of LIC. By contrast, in patients without a serum fer-
ritin response 52% showed an LIC response and 48% did
not. This has important implications for the management of
patients; a serum ferritin response is more likely to indicate
a downward trend in LIC, whereas a lack of serum ferritin
Figure 1 Proportion of serum ferritin responders and non-responders with or without an LIC decrease (A), and the proportion of serum ferritin
non-responders with an LIC response by LIC decrease ≤ or >1 mg Fe/g dw (upper; B) and mean LIC decrease from study baseline in serum fer-
ritin non-responders with an LIC response by LIC decrease ≤ or >1 mg Fe/g dw (lower; B). Most patients without a serum ferritin response, but
with an LIC response experienced a clinically meaningful reduction in LIC. dw, dry weight; IQR, interquartile range; LIC, liver iron concentration.
Figure 2 The proportion of serum ferritin responders by study baseline iron burden categories of serum ferritin <4000 or ≥4000 ng/mL (A) and
the proportion of serum ferritin responders and non-responders with an LIC response by study baseline iron burden categories of serum ferritin
<4000 or ≥4000 ng/mL (B). LIC, liver iron concentration.
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response is equally likely to indicate an LIC decrease as no
LIC decrease. Overall, these results show that all patients
should receive LIC determination by MRI as serum ferritin
trends can be misleading. Only where resources for LIC
measurement are severely limited should follow-up LIC
measurement be targeted to patients in whom serum ferritin
is not responding; subsequent demonstration of an LIC
decrease in these patients would, therefore, indicate treat-
ment effectiveness and unnecessary changes in chelation
dose or regimen could be avoided. Such therapeutic modiﬁ-
cations could then be targeted only to patients who fail to
demonstrate both a serum ferritin and an LIC decrease.
A recent retrospective cohort study conducted in 134
patients with transfusion-dependent anaemia (primarily
sickle-cell disease and thalassaemia) over a period of up to
9 yr showed that the change in serum ferritin and change in
LIC in patients with thalassaemia was concordant 46% of
the time (13). Despite patients receiving several different
chelation regimens, which may affect the relationship
between serum ferritin and LIC (24), and different analytical
methods, Puliyel et al. (13) showed that overall the change
in serum ferritin was in the same direction as the change in
LIC 74% of the time, which is similar to the 80% of
patients we observed with both a serum ferritin and an LIC
response.
A second aspect of our study was to determine how the
relationship between changes in serum ferritin and changes
in LIC was affected by study baseline serum ferritin values.
This is of practical importance because clinicians need to
know whether serum ferritin changes are more or less reli-
able as an indicator of body iron removal when baseline
serum ferritin levels are high. A ROC analysis was under-
taken for LIC and serum ferritin that indicated serum ferritin
values of between 3500 and 4000 ng/mL were appropriate
to predict severe liver iron burden of at least 20 mg Fe/g
dw, although these data should be interpreted with caution
because of the low sensitivity of serum ferritin and LIC at
high values. Nonetheless, in addition to the fact that a
greater proportion of serum ferritin derives from damaged
hepatocytes at serum ferritin levels >4000 ng/mL (26), this
justiﬁed our analyses of serum ferritin and LIC trends
according to serum ferritin categories of <4000 or ≥4000 ng/mL
at study baseline.
Our ﬁndings showed that, generally, the relationship
between absolute serum ferritin and LIC values at study
baseline was not signiﬁcant for serum ferritin values of
≥4000 ng/mL, or LIC values of ≥15 mg Fe/g dw. By con-
trast, the relationship between change in LIC and change in
serum ferritin was signiﬁcant at both high and low baseline
serum ferritin values, although this was stronger when base-
line serum ferritin was lower. Despite the relatively poor
utility of high serum ferritin values to predict absolute LIC,
a downward trend in serum ferritin indicates LIC response
in 70% of patients with serum ferritin ≥4000 ng/mL.
Moreover, as with the whole patient cohort, a lack of serum
ferritin response is a poor differentiator for LIC response
versus non-response at high serum ferritin levels. Therefore,
when MRI resources are severely limited, measurement can
be prioritised for patients without a serum ferritin response,
irrespective of baseline serum ferritin values.
A number of underlying factors may contribute to the
weak relationship between absolute serum ferritin and LIC
at the higher end of the iron burden spectrum. It has been
previously reported that FerriScan becomes less sensitive at
higher LIC (35), particularly at values >30 mg Fe/g dw
(27), which may complicate understanding of the relation-
ship between LIC and serum ferritin at high iron burdens.
Secondly, the physiological origin of serum ferritin may also
be relevant (26). Thirdly, above LIC values of between 15
and 20 mg Fe/g dw, ongoing hepatic damage, increased
liver enzyme leakage and consequently hepatocellular ferritin
leakage are observed (36).
A number of other observations are notable from this
study. More than 60% of patients had previously received
deferoxamine (Table 1). Data from both preclinical studies
(37) and clinical observations (24) suggest deferoxamine
accesses liver and macrophage iron pools differently to
deferasirox, which in turn may alter the relationship between
LIC and serum ferritin, and between changes in these param-
eters over time. Additionally, it has been suggested that, dur-
ing the initial months of deferasirox therapy, serum ferritin
response may lag behind the LIC response (38). Such an
effect would occur if hepatocellular iron, which is rapidly
targeted in vitro by deferasirox (39), were targeted by defer-
asirox faster than macrophage (Kupffer cell) iron, which is
the major contributor to serum ferritin levels (26, 38). It
would be of interest to examine this relationship over shorter
time periods to address whether serum ferritin trends in the
ﬁrst 3–6 months of treatment with deferasirox reﬂect early
LIC responses. However, this study shows that after 1 yr of
deferasirox, changes in serum ferritin reﬂect changes in LIC
and the relationship between the two variables is not signiﬁ-
cantly altered, in most cases. Additionally, these results sug-
gest that serum ferritin levels may better predict liver iron
levels once patients have been receiving effective chelation
therapy for at least 1 yr and iron burden is lower. However,
it must be noted that there are many other variables that
may impact upon treatment with deferasirox, including treat-
ment adherence, which is particularly relevant outside of the
clinical trial setting.
A further implication of this analysis is that iron intake
rate and chelation dose should be routinely examined in
patients in whom serum ferritin and/or LIC are not respond-
ing. Of note, deferasirox dose was suboptimal in all patients,
but particularly in those without a serum ferritin or LIC
response; these patients received lower deferasirox doses and
had a higher transfusional iron intake compared with patients
who experienced a response. These insights highlight the
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necessity of tailoring dose to a patient’s individual needs
and ensuring appropriate management of iron overload.
Management of deferasirox dose at low serum ferritin val-
ues is increasingly becoming an area of interest. Current
drug labelling for deferasirox suggests stopping treatment
when serum ferritin values reach 500 ng/mL (40). However,
gradual downward dose adjustment, without dose interrup-
tion, has been proposed as a preferable approach to achieve
a ‘soft landing’, with a reduced possibility of over chelation;
this has been shown in patients treated with a combination
of deferiprone and deferoxamine (41), or deferiprone and
deferasirox (42). Prospective studies are required to charac-
terise how low serum ferritin values can be most safely
achieved without over chelation. In the context of this paper,
which highlights the caveats of serum ferritin for determin-
ing trends in LIC, measurement of LIC by MRI is likely to
be important in patients with low serum ferritin values to
guide deferasirox dose reduction or discontinuation.
In conclusion, this study clariﬁes how LIC determination
can be used to aid interpretation of serum ferritin trends in
patients with transfusion-dependent thalassaemia receiving
deferasirox treatment. The chelator dose typically needs to
be adjusted for each individual patient; both absolute levels
and overall trends in serum ferritin are used to guide dose
adjustments. However, this analysis demonstrates that,
where possible, MRI determination of LIC should be
offered for all transfused patients because of the limitations
of using serum ferritin alone. This is particularly important
in the absence of a downward trend in serum ferritin,
because roughly equal proportions of patients will be
responding, or not, in terms of LIC. Interpretation of serum
ferritin trends can be particularly challenging at very high
serum ferritin levels. However, these ﬁndings show that a
clear downward trend in serum ferritin is a reasonable indi-
cator of a decrease in LIC (and hence body iron) in 80% of
cases, at both high and low baseline serum ferritin levels.
Based on the data presented here, when the availability of
MRI is limited, LIC determination by MRI could be priori-
tised for patients without a serum ferritin response. Dose
adjustment, or change of regimen, could then be performed
in patients without a downward trend in LIC. As the patient
population had a high degree of iron overload, it would be
valuable to examine the relationship between serum ferritin
and LIC trends as patients approach lower, near-‘normal’
serum ferritin levels, so that doses can be adjusted appropri-
ately to achieve a ‘soft landing’ and to minimise the risk of
over chelation.
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Figure S1. Relationship between serum ferritin and LIC
at study baseline* (A, C) and change from study baseline
(B, D) by study baseline iron burden categories of serum
ferritin <4000 or ≥4000 ng/mL (A, B) and LIC <15 or
≥15 mg Fe/g dw (C, D). A higher positive correlation was
observed between serum ferritin and LIC at baseline (A),
and for change from baseline (B), when baseline serum fer-
ritin was <4000 ng/mL (grey) than when baseline serum fer-
ritin was ≥4000 ng (black). A higher positive correlation
was observed between serum ferritin and LIC at baseline
(C), and for change from baseline (D), when baseline LIC
was <15 ng/mL (grey) than when baseline LIC was ≥15 ng/
mL (black).
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